Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.39
-0.13 (-1.99%)
At close: Nov 13, 2026, 4:00 PM EST
6.51
+0.12 (1.88%)
After-hours: Nov 13, 2026, 7:53 PM EST

Revenue

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Moderna, United States Revenue
35.66M37.25M62.79M
Bristol-Myers Squibb (BMS), United States Revenue
-11.02M78.10M
Genmab, Denmark Revenue
--14.95M
Total Revenue from Collaboration Agreements
43.44M48.27M155.84M
Revenue (Other)
-35.66M-37.25M-62.79M
Revenue (Total)
43.44M48.27M155.84M

Key Performance Indicators

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Research and Development Expenses
241.51M183.83M148.08M